Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers Insights Derived From the FOURIER Trial
Article
Arrieta, Alejandro, Hong, Jonathan C, Khera, Rohan et al. (2017). Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers Insights Derived From the FOURIER Trial
. JAMA CARDIOLOGY, 2(12), 1369-1374. 10.1001/jamacardio.2017.3655
Arrieta, Alejandro, Hong, Jonathan C, Khera, Rohan et al. (2017). Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers Insights Derived From the FOURIER Trial
. JAMA CARDIOLOGY, 2(12), 1369-1374. 10.1001/jamacardio.2017.3655